Research ArticleCancer

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

See allHide authors and affiliations

Science Translational Medicine  12 Dec 2018:
Vol. 10, Issue 471, eaau0417
DOI: 10.1126/scitranslmed.aau0417

Article Information

vol. 10 no. 471

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication May 1, 2018
  • Resubmitted August 4, 2018
  • Accepted for publication October 31, 2018
  • .

Author Information

  1. Praveen K. Bommareddy1,2,
  2. Salvatore Aspromonte 2,
  3. Andrew Zloza2,3,
  4. Samuel D. Rabkin4 and
  5. Howard L. Kaufman5,6,*
  1. 1School of Graduate Studies, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
  2. 2Section of Surgical Oncology Research, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
  3. 3Division of Hematology, Oncology, and Cell Therapy, Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA.
  4. 4Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA.
  5. 5Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
  6. 6Replimune Inc., Woburn, MA 01801, USA.
  1. *Corresponding author. Email: hlkaufman{at}mgh.harvard.edu

Altmetric

Article usage

Article usage: December 2018 to November 2020

AbstractFullPdf
Dec 201870601619847
Jan 2019840357251
Feb 2019479117109
Mar 20194479399
Apr 20193217266
May 20192957765
Jun 20193215343
Jul 20194774146
Aug 201910003842
Sep 20199855453
Oct 20198304260
Nov 20196322845
Dec 201924620973
Jan 202011222115
Feb 202022293180
Mar 202010154123
Apr 202014173134
May 202018121151
Jun 202023113108
Jul 202023142119
Aug 202017118112
Sep 202037160138
Oct 202024171174
Nov 2020158536

Stay Connected to Science Translational Medicine

Navigate This Article